Eatontown, NJ 26 (June 26, 2017) – West-Ward Pharmaceuticals, a wholly owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announces the promotion of Spiro Gavaris to President of the US Injectables Commercial Operations and the appointment of Craig Heneghan as Executive Vice President Commercial Development Strategy for the US Generics Division.
These leadership changes follow the announcement today by Hikma of the planned retirement at the end of 2017 of Michael Raya, CEO of the US business, and additional leadership and organizational changes that will bring greater organisational focus and alignment, and ensure a strong focus on the different and changing needs of the customers in the US.
Mr. Gavaris has been promoted to President of the US Injectables Commercial Operations, with responsibility for Sales & Marketing, Commercial Development and Business Development. Previously, he led the US Sales & Marketing organization, both Injectables and Non-Injectables for Hikma’s West-Ward Pharmaceuticals. He will also continue to manage the US Commercial Operations group that supports both business units.
Mr. Heneghan will be responsible for the leadership, and implementation of the commercial development initiatives for the US Generics business, as well as providing input into the long-range planning and goal-setting to achieve the growth potential of the division in the US. Prior to joining Hikma, Mr. Heneghan was the founding President of Red Oak Sourcing, a stand-alone joint venture between CVS Health and Cardinal Health and the largest generic pharmaceutical sourcing entity in the United States. He will report to Brian Hoffmann, President of US Generics at Hikma.
Michael Raya, CEO of West-Ward, commented, “We are thrilled that Craig is joining our team. His well-established leadership skills and depth of experience within the generics sector will bring a functional excellence focus to West-Ward and help further Hikma’s standing within the generic pharmaceutical industry.” Mr. Raya added, “Spiro has shown strong leadership since joining West Ward in 2010, and we are delighted that he can focus now exclusively on the Injectables customers, ensuring we are able to continue to meet their needs in the competitive and changing US environment.”
-- ENDS --
Keri Butler, West-Ward Pharmaceuticals
West-Ward is a wholly owned division of Hikma Pharmaceuticals PLC, a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.